Abstract
To study the changes in the quantity of circulating immune complexes in myocardial infarction two serial investigations were performed in 45 and 63 patients, respectively. For the detection of circulating immune complexes in the first series, two methods, a complement consumption test and a Clq-solubility test were used. In the second series, a polyethylene glycol (PEG)-precipitation assay was added to these methods. The incidence of circulating immune complexes was studied on the first, third, seventh, 14th, and 21st day. On the first day the complexes were detected in 59% of the patients. Their occurrence increased in the further samplings to 77%, but from the seventh day their concentration decreased and on the 21st day they were detected in 63%. Three types of changes in the level of circulating immune complexes could be shown. In type I immune complexes were detected in the first days after the onset of the infarction, then, after a gradual decrease, the results became negative. In type II immune complexes appeared in the second to third week and their quantity did not alter during the entire observation period. In type III the circulating immune complexes could be detected throughout the whole period of the study. These changes in their concentration were frequently associated with the clinical course of the disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cochrane C. G., Koffler D. Immune complex disease in experimental animals and man. Adv Immunol. 1973;16(0):185–264. doi: 10.1016/s0065-2776(08)60298-9. [DOI] [PubMed] [Google Scholar]
- Farrell C., Bloth B., Nielsen H., Daugharty H., Lundman T., Svehag S. E. A survey for circulating immune complexes in patients with acute myocardial infarction. Use of a C1q-binding assay with soluble protein A as indicator. Scand J Immunol. 1977;6(12):1233–1240. doi: 10.1111/j.1365-3083.1977.tb00362.x. [DOI] [PubMed] [Google Scholar]
- Füst G., Szondy E., Székely J., Nánai I., Gerö S. Studies on the occurrence of circulating immune complexes in vascular diseases. Atherosclerosis. 1978 Feb;29(2):181–190. doi: 10.1016/0021-9150(78)90006-0. [DOI] [PubMed] [Google Scholar]
- Gabriel A., Jr, Agnello V. Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor. J Clin Invest. 1977 May;59(5):990–1001. doi: 10.1172/JCI108722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hasková V., Kaslík J., Ríha I., Matl I., Rovenský J. Simple method of circulating immune complex detection in human sera by polyethylene glycol precipitation. Z Immunitatsforsch Immunobiol. 1978 Jun;154(4):399–406. [PubMed] [Google Scholar]
- Johnson A. H., Mowbray J. F., Porter K. A. Detection of circulating immune complexes in pathological human sera. Lancet. 1975 Apr 5;1(7910):762–765. doi: 10.1016/s0140-6736(75)92433-2. [DOI] [PubMed] [Google Scholar]
- Mathews J. D., Whittingham S., Mackay I. R. Autoimmune mechanisms in human vascular disease. Lancet. 1974 Dec 14;2(7894):1423–1427. doi: 10.1016/s0140-6736(74)90077-4. [DOI] [PubMed] [Google Scholar]
- REITMAN S., FRANKEL S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957 Jul;28(1):56–63. doi: 10.1093/ajcp/28.1.56. [DOI] [PubMed] [Google Scholar]
- Rossen R. D., Reisberg M. A., Hersh E. M., Gutterman J. U. The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst. 1977 May;58(5):1205–1215. doi: 10.1093/jnci/58.5.1205. [DOI] [PubMed] [Google Scholar]
- Zubler R. H., Nydegger U., Perrin L. H., Fehr K., McCormick J., Lambert P. H., Miescher P. A. Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease. J Clin Invest. 1976 May;57(5):1308–1319. doi: 10.1172/JCI108399. [DOI] [PMC free article] [PubMed] [Google Scholar]